JCR Pharmaceuticals Co., Ltd. provided earnings guidance for second quarter ending September 30, 2020 and full year ending March 31, 2021. For the half year ending September 30, 2020, the company expects to report net sales of JPY 14,400 million, operating income of JPY 3,600 million and profit attributable to owners of the parent of JPY 2,900 million or JPY 94.07 per share. For the full year ending March 31, 2021, the company expects to report net sales of JPY 27,200 million, operating income of JPY 6,000 million and profit attributable to owners of the parent of JPY 4,800 million or JPY 155.70 per share.